Minimal Residual Disease Negativity Does Not Overcome Poor

  • Slides: 12
Download presentation
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study Chutima Kunacheewa, Hans C. Lee, Krina Patel, Sheeba Thomas, Behrang Amini, Samer Srour, Qaiser Bashir, Yago Nieto, Muzzaffar H. Qazilbash, Donna M. Weber, Lei Feng, Robert Z. Orlowski, Pei Lin, Elisabet E. Manasanch Clinical Lymphoma, Myeloma and Leukemia Volume 20 Issue 5 Pages e 221 -e 238 (May 2020) DOI: 10. 1016/j. clml. 2020. 01. 001 Copyright © 2020 Elsevier Inc. Terms and Conditions

Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI:

Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI:

Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI:

Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 4 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 4 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 5 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 5 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 6 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 6 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 7 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 7 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 8 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 8 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions